US Patent 5,502,077: Scope, Claim Construction, Expiration, and Omega-3 Patent Landscape

US Patent 5,502,077 protected oral treatment or prophylaxis of hypertriglyceridemia using an EPA/DHA fatty-acid mixture, generally at 1 to 10 grams per day. The patent was directed to the composition profile associated with Omacor, later marketed in the United States as Lovaza. Its strongest commercial coverage applied to ethyl-ester mixtures containing approximately 46.5% EPA and 37.5% DHA, with an EPA:DHA ratio near 1.24:1. The patent expired in 2013 and no longer creates a blocking right against generic or competing omega-3 products. [1][2]

What does US Patent 5,502,077 protect?

The patent protects a method of treating or preventing hypertriglyceridemia by orally administering a defined mixture of long-chain omega-3 fatty acids. Claim 1 requires all of the following:

Claim element	Required limitation
Patient and disease	Human patient with hypertriglyceridemia
Route	Oral administration
Therapeutic purpose	Treatment or prophylaxis
Composition	Active ingredients consist essentially of a fatty-acid mixture
EPA and DHA content	At least 80% by weight of the mixture is EPA plus DHA
EPA:DHA ratio	Between 1:2 and 2:1
Dose	1 to 10 grams per day of the fatty-acid mixture

The claim is a method claim, not a broad claim to EPA, DHA, fish oil, or omega-3 fatty acids generally. An accused product must be administered for the claimed therapeutic purpose and must satisfy the specified composition and dosage limitations.

The phrase “consist essentially of” is commercially important. It permits components that do not materially alter the claimed invention, but it excludes an active pharmaceutical ingredient that changes the basic character of the claimed fatty-acid therapy. A product containing omega-3 fatty acids together with a separate active drug could create a claim-construction issue, depending on whether the composition is treated as having additional active ingredients outside the claimed mixture.

How do the dependent claims narrow the patent scope?

The dependent claims create progressively narrower composition profiles.

Claim	Additional limitation	Practical significance
1	At least 80% EPA plus DHA; 1:2 to 2:1 ratio; 1-10 g/day	Core method claim
2	At least 85% long-chain omega-3 fatty acids	Excludes lower-purity fish-oil mixtures
3	EPA 40-60%; DHA 25-45%	Targets an EPA/DHA-rich commercial concentrate
4	EPA:DHA ratio 1:1 to 2:1	Narrows the ratio toward EPA-balanced products
5	At least 4.5% other C20-C22 fatty acids	Adds a compositional fingerprint
6	At least 3% other C20-C22 omega-3 fatty acids	Narrows claim 5 to additional omega-3 constituents
7	At least 1% heneicosapentaenoic acid	Adds a specific minor fatty acid
8	Esterified fatty acids	Covers ester formulations
9	Ethyl-ester form	Directly targets omega-3 ethyl esters
10	Salt form	Covers salt formulations
11	Free-acid form	Covers unesterified fatty acids
12	Claim 7 profile; at least 85% EPA plus DHA; ethyl esters	Narrowest product-specific method claim

Claims 5 through 7 are not ordinary purity claims. They describe additional minor fatty acids that can function as an analytical fingerprint of the source oil or manufacturing process. Such limitations would have made infringement dependent on validated compositional testing rather than only on label strength.

Does Lovaza fit the US 5,502,077 claims?

Lovaza was the principal commercial product associated with the patent family. The FDA label identifies each 1-gram capsule as containing omega-3-acid ethyl esters, including approximately 465 mg of EPA ethyl ester and 375 mg of DHA ethyl ester. [2]

The labeled EPA and DHA profile maps closely to the dependent claims:

Lovaza characteristic	Claim comparison
EPA content	Approximately 46.5% of capsule content
DHA content	Approximately 37.5%
EPA:DHA ratio	Approximately 1.24:1
EPA plus DHA	Approximately 84%
Form	Ethyl esters
Indication	Severe hypertriglyceridemia
Typical dosage	4 grams daily
Claim 3	Likely within 40-60% EPA and 25-45% DHA
Claim 4	Within 1:1 to 2:1 EPA:DHA
Claim 9	Ethyl-ester limitation
Claim 12	Potentially applicable if the minor-acid and 85% composition limitations are met

The exact fit of claims 5, 6, 7, and 12 depends on the product’s tested fatty-acid profile. The FDA label alone does not establish whether a particular lot contains at least 4.5% qualifying C20-C22 fatty acids, at least 3% qualifying non-EPA/non-DHA omega-3 fatty acids, or at least 1% heneicosapentaenoic acid.

What is the claim scope for generic omega-3 ethyl esters?

A generic product could fall within claim 1 if it satisfies the composition, ratio, dosage, and method-of-use limitations. The key infringement questions would have been:

Whether the product contains at least 80% EPA plus DHA by weight.
Whether the EPA:DHA ratio falls between 1:2 and 2:1.
Whether the product is administered at 1 to 10 grams per day of the fatty-acid mixture.
Whether the labeled or actual indication includes treatment or prophylaxis of hypertriglyceridemia.
Whether the product’s active ingredients consist essentially of the claimed fatty-acid mixture.

A product containing only EPA, such as icosapent ethyl, would not satisfy the EPA-plus-DHA requirement because it lacks the claimed combination. A low-DHA or DHA-free product would also fall outside the express ratio limitation.

A product with EPA and DHA but a ratio outside 1:2 to 2:1 would avoid claim 1. For example, a predominantly DHA product with an EPA:DHA ratio below 1:2 would not meet the independent ratio requirement. A predominantly EPA product with a ratio above 2:1 would also fall outside claim 1, even if it contained more than 80% combined EPA and DHA.

When did US Patent 5,502,077 expire?

US Patent 5,502,077 issued on March 26, 1996. Its patent term expired in 2013, with the USPTO patent record identifying March 26, 2013 as the expiration date. [1]

Event	Date
US patent grant	March 26, 1996
Base patent expiration	March 26, 2013
Current enforceability	Expired
Current generic blocking effect	None

The patent’s expiration ended the ability to enforce its composition and method claims against later generic products. Patent expiration does not erase the historical significance of the claims, but it removes the patent from current exclusionary analysis.

What was the Orange Book status of Lovaza?

Lovaza was approved by the FDA in 2004 under NDA 021654 for severe hypertriglyceridemia. The product was initially marketed as Omacor outside the United States and as Lovaza in the United States. [2][3]

The historical Lovaza patent estate included multiple patents directed to the omega-3 composition, manufacturing characteristics, and therapeutic use. US Patent 5,502,077 was one of the principal early patents associated with the product. Orange Book listings for a drug can include patents beyond the patent most closely matched to the commercial formulation. [3]

FDA Orange Book data must be distinguished from the underlying patent status:

An Orange Book listing identifies a patent submitted by the NDA holder.
It does not determine infringement.
It does not establish validity.
An expired patent cannot support a current exclusionary period.
Patent listing disputes and Paragraph IV certifications are separate from patent expiration.

The current commercial availability of generic omega-3-acid ethyl esters reflects the expiration of the principal Lovaza patent barriers and subsequent generic approvals.

Which products compete with the patent-protected EPA/DHA profile?

Lovaza and generic omega-3-acid ethyl esters

Lovaza and its generic equivalents are the closest products to the claimed profile. They use esterified EPA and DHA and are administered for severe hypertriglyceridemia. Generic products typically rely on the same active-ingredient category but are not required to reproduce the brand’s exact trade dress or inactive ingredients.

Epanova

Epanova was an FDA-approved omega-3 product containing free fatty acids rather than ethyl esters. It contained a mixture of EPA, DHA, and other omega-3 fatty acids. [4] Its free-acid formulation implicates the formulation branch represented by claim 11, but the 5,502,077 patent had already expired by the time Epanova became commercially relevant.

Vascepa and generic icosapent ethyl

Vascepa contains icosapent ethyl, an EPA-only ethyl ester. It does not satisfy the EPA-plus-DHA combination required by claim 1. Its relevant patent estate was directed to EPA-only treatment and cardiovascular-risk reduction, not the specific EPA/DHA combination in US 5,502,077. [5]

Prescription fish-oil and dietary supplements

Nonprescription fish-oil products can contain EPA and DHA within the claimed ratio, but infringement historically would have required the method, dosage, therapeutic purpose, and composition elements to align. Dietary supplements marketed for general wellness are less likely to satisfy the claimed hypertriglyceridemia treatment or prophylaxis limitation.

What patent landscape surrounded US 5,502,077?

The relevant landscape had four categories.

Core EPA/DHA composition patents

These patents covered specific ratios, purity levels, minor fatty-acid constituents, and ester forms. US 5,502,077 is in this category. Its claims were designed around an EPA/DHA concentrate rather than unprocessed fish oil.

Therapeutic-use patents

Later patents in the Lovaza and omega-3 field addressed treatment of hypertriglyceridemia, dosing, lipid effects, and patient populations. These patents could remain relevant after expiration of an earlier composition patent if their claims covered a distinct method or dosage regimen.

Formulation and delivery patents

Other patents addressed soft-gel capsules, ethyl-ester stabilization, oxidation control, purification, and manufacturing methods. These patents can create commercial barriers even when the active ingredient itself is off patent. For an oral omega-3 product, the most relevant formulation issues include:

oxidation and peroxide control;
encapsulation of high-volume oil doses;
odor reduction;
capsule fill weight;
stability over shelf life;
purification of environmental contaminants;
batch-to-batch control of EPA, DHA, and minor fatty acids.

Product-specific regulatory exclusivity

Lovaza’s regulatory exclusivity was separate from patent protection. The product was approved in 2004, and any applicable FDA exclusivity period would have expired before the modern generic market developed. Regulatory exclusivity did not extend the life of US Patent 5,502,077. [2][3]

Were there Paragraph IV challenges to Lovaza?

Generic applicants seeking approval before expiration of listed patents could submit Paragraph IV certifications under the Hatch-Waxman Act. Those certifications assert that a listed patent is invalid, unenforceable, or not infringed.

Lovaza’s generic-entry process involved patent certifications and patent litigation concerning the listed Lovaza patent estate. The commercial impact was limited after the relevant patents expired. FDA approval of generic omega-3-acid ethyl ester products followed the end of the principal patent protection period. [3][6]

The strategic importance of a Paragraph IV challenge to US 5,502,077 is now historical. Because the patent expired in 2013, a current applicant would not need to overcome this patent through an early launch strategy. The relevant risks now arise from other unexpired patents, regulatory requirements, product quality, and manufacturing capability.

What manufacturing and IP barriers remain after patent expiration?

Patent expiration does not eliminate technical barriers. A generic manufacturer must still produce a consistent EPA/DHA concentrate with validated composition and stability.

The principal technical barriers are:

Barrier	Commercial effect
Fatty-acid purification	Controls EPA/DHA concentration and removes contaminants
Oxidation control	Protects potency, taste, and shelf life
Compositional consistency	Supports ANDA specifications and batch release
Ethyl-ester production	Requires controlled esterification and purification
Capsule manufacturing	Requires large fill volumes and specialized soft-gel equipment
Analytical testing	Measures EPA, DHA, minor omega-3s, and impurities
Supply chain	Depends on marine or algal oil sources and refining capacity

The specific heneicosapentaenoic-acid limitation in claim 7 also illustrates why source-material control matters. Minor fatty-acid constituents can vary with species, harvest conditions, extraction, purification, and blending. A manufacturer can design around such limitations by changing the composition, but the product must still satisfy FDA quality and equivalence requirements.

How strong was the patent estate for US 5,502,077?

The patent was commercially strong while unexpired because it combined a therapeutic method with a narrow but commercially important composition profile. Its strongest features were:

a clinically recognized indication;
a dose range covering the approved 4-gram daily regimen;
an EPA:DHA ratio matching the commercial product;
dependent claims covering ethyl esters;
additional claims directed to minor fatty-acid constituents.

Its weaknesses were equally clear:

the independent claim required both EPA and DHA;
products outside the 1:2 to 2:1 ratio were excluded;
the claim required a specified daily dose;
some dependent claims required difficult-to-prove minor constituents;
the patent had a finite term ending in 2013;
later products could use EPA-only or different formulation strategies.

The patent’s present strength is zero as an exclusionary right because it has expired. Its remaining value is prior-art and freedom-to-operate relevance.

What generic launch risks exist for EPA/DHA products today?

A current generic manufacturer faces little risk from US Patent 5,502,077 itself. The principal risks are:

Undiscovered later patents covering dosage, patient selection, formulation, or manufacturing.
ANDA approval delays caused by product-quality deficiencies.
Failure to demonstrate pharmaceutical equivalence.
Inconsistent EPA/DHA ratios between batches.
Oxidative degradation and stability failures.
Commercial price erosion after multiple generic entrants.
Supply constraints involving purified marine oils or capsule production.
Separate patents covering combination therapy or cardiovascular indications.

Biosimilar risk is not relevant to this product class. Lovaza is a small-molecule mixture of fatty-acid ethyl esters, not a biologic. The applicable pathway is an ANDA or, depending on product characteristics, another small-molecule FDA pathway rather than a biosimilar application under the Public Health Service Act.

How does US 5,502,077 compare with EPA-only patents?

Issue	US 5,502,077	EPA-only products such as Vascepa
Active profile	EPA plus DHA	EPA only
Required ratio	EPA:DHA between 1:2 and 2:1	No DHA ratio
Main form	Ethyl esters, free acids, salts, or esters under dependent claims	Icosapent ethyl
Core indication	Hypertriglyceridemia treatment or prophylaxis	Hypertriglyceridemia and, under later labeling, cardiovascular risk reduction
Patent status	Expired in 2013	Separate later patent estate
Biosimilar pathway	Not applicable	Not applicable
Main design-around	Alter EPA:DHA ratio or remove DHA	Already outside the EPA/DHA combination claim

Key Takeaways

US Patent 5,502,077 claimed oral treatment or prophylaxis of hypertriglyceridemia using 1 to 10 grams per day of an EPA/DHA mixture.
Claim 1 required at least 80% combined EPA and DHA and an EPA:DHA ratio between 1:2 and 2:1.
Claims 3, 4, 9, and potentially 12 closely tracked the Lovaza omega-3 ethyl-ester profile.
Claims 5 through 7 added minor-fatty-acid limitations that could require lot-specific analytical testing.
Lovaza’s labeled EPA/DHA profile was broadly consistent with the claimed composition.
The patent expired in 2013 and no longer blocks generic launch.
Vascepa and other EPA-only products fall outside the express EPA-plus-DHA combination requirement.
Current commercial risk lies in later patents, FDA approval, manufacturing quality, oxidation control, and supply economics.
Biosimilar analysis is not applicable because prescription omega-3 products are small-molecule fatty-acid preparations.

FAQs

Is US Patent 5,502,077 still enforceable?

No. The patent expired in 2013 and does not create a current exclusionary right.

Did US Patent 5,502,077 cover Lovaza?

Yes. Its EPA/DHA composition, ratio, ethyl-ester form, and 4-gram daily regimen closely corresponded to the Lovaza product profile.

Does Vascepa infringe US Patent 5,502,077?

Vascepa contains EPA-only icosapent ethyl and does not contain the claimed EPA/DHA combination. It therefore falls outside the express combination requirement of claim 1.

Can a fish-oil supplement infringe the patent claims?

The patent is expired, so no current infringement liability arises under this patent. Historically, a supplement would have needed to satisfy the composition, dosage, therapeutic-purpose, and administration limitations.

Is a generic omega-3 product a biosimilar to Lovaza?

No. Omega-3-acid ethyl ester products are small-molecule drug products. Generic approval generally proceeds through the ANDA framework, not the biosimilar pathway.

References

United States Patent No. 5,502,077. (1996). Pharmaceutical composition containing eicosapentaenoic acid and docosahexaenoic acid. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2004). Lovaza prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (2014). Epanova prescribing information. FDA.
U.S. Food and Drug Administration. (2012). Vascepa prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments, patent certifications, and generic drug approvals. FDA.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	8819110	Aug 11, 1988

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	398779	⤷ Start Trial
Austria	A191889	⤷ Start Trial
Australia	3896789	⤷ Start Trial
Australia	616784	⤷ Start Trial
Belgium	1002547	⤷ Start Trial
Canada	1337548	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,502,077

Summary for Patent: 5,502,077